News and Events

BioPontis Alliance profiled by Nature Biotechnology in “New models emerge for commercializing university assets” article
Learn more!
BioPontis Alliance CSO Henri Lichenstein to Speak on November 3 at Rutgers CIVET Seminar
Learn more
BioPontis Alliance is Highlighted in FasterCures’ Summary of Financial Innovations for Translational Research Lab
Learn more

BioPontis Alliance

A new business model fitted to address the challenge of how to both finance and execute the effective translation of academic biomedical discoveries into viable therapeutic candidates suitable for the biopharmaceutical-industry pipelines of tomorrow.

  • Founded in 2009
  • Established hybrid business structure combining asset-based fund investment with industry-experienced asset development
  • Completed unique economic and IP-sharing agreements with 7 leading research universities and institutions
  • Established unique knowledge-capital and translational-development agreements with top three pharmaceutical companies
  • Formed Translational Development Network specific to preclinical-development space
  • Actively sourcing assets: in excess of 300 reviewed